Solid forms of desvenlafaxine
AssigneeAlparis, S.A. De C.V.
InventorsJorge Guillermo DOMÍNGUEZ CHÁVEZ, Karina MONDRAGÓN VÁSQUEZ, Hugo MORALES ROJAS, Dea HERRERA RUIZ, Herbert HÖPFL, Reyna REYES MARTÍNEZ, Javier HERNÁNDEZ ILLESCAS, Juan Pablo SENOSIAIN PELÁEZ
Life of this patent
Estimating the term…
Abstract
The present invention refers to new amorphous and crystalline solid forms of desvenlafaxine, also known as O-desmethylvenlafaxine or desmethylvenlafaxine, and to its salts, solvates, hydrates and polymorphs thereof, as well as to their use in the manufacture of a pharmaceutical composition useful in the treatment of depression and/or as a selective serotonin and norepinephrine reuptake inhibitor and also in menopause-associated vasomotor disorders.
Claims13
A crystalline or amorphous solid compound formed by the selective serotonin and noradrenaline reuptake inhibitor desvenlafaxine (or DSV) and a co-former X, wherein X comprises one or more hydroxyl groups and a carboxyl group, wherein desvenlafaxine and X form the solid compound through ionic interactions or non-covalent intermolecular forces;
- or any solvate, hydrate or polymorph of the solid compound.
A process for purifying a solid compound formed by desvenlafaxine and a co-former X, wherein X comprises one or more hydroxyl groups and a carboxyl group, the method comprising:
- a) Heating a mixture of the solid compound and a polar solvent until dissolution;
- b) Concentrating the mixture until solvent volume reaches one fourth of its original value, and cooling down the resulting system to 10° C.-15° C.;
- c) Filtrating the system of step b), and washing the isolated solid with a polar solvent and drying the washed isolated solid, wherein the polar solvent is selected from the group consisting of methanol, ethanol, isopropyl alcohol, hexane, and acetone.
Dependencies are inferred from the claim text.